News Home

Analyst Rating: Will Phathom Pharmaceuticals Inc (PHAT) Stock Do Better Than the Market?

Thursday, October 28, 2021 09:57 AM | InvestorsObserver Analysts
Analyst Rating: Will Phathom Pharmaceuticals Inc (PHAT) Stock Do Better Than the Market?

Wall Street is positive on Phathom Pharmaceuticals Inc (PHAT). On average, analysts give the stock a Strong Buy rating. The average price target is $59.25, which means analysts expect the stock to climb by 121.25% over the next twelve months. That average ranking earns the stock an Analyst Rating of 64, which is better than 64% of stocks based on data compiled by InvestorsObserver.

Overall Score - 4.7
Wall Street analysts are rating PHAT a Strong Buy today. Find out what this means to you and get the rest of the rankings on PHAT!

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Phathom Pharmaceuticals Inc Stock Today?

Phathom Pharmaceuticals Inc (PHAT) stock is trading at $26.78 as of 9:56 AM on Thursday, Oct 28, a gain of $2.01, or 8.14% from the previous closing price of $24.76. The stock has traded between $26.14 and $27.32 so far today. Volume today is below average. So far 68,556 shares have traded compared to average volume of 169,481 shares. Click Here to get the full Stock Report for Phathom Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App